Webinar: Negotiating Clinical Research Organization (Cro) Contracts – Understanding and Mitigating FX...


Watch the webinar replay [PLAYBACK]
Download the presentation (PDF)


Large spending on clinical research projects in a foreign country can expose life science companies to potentially millions in foreign currency risks.  A successful clinical research relationship may depend on rigorous risk-hedged planning and management. 

Hear SVB's Life Science and Foreign Exchange teams engage in a dialogue covering:

  • How to leverage SVB's insight and solutions to improve contract economics
  • Case studies of how FX hedging and negotiation tactics can affect the bottom line
  • Common contractual terms to be aware of when negotiating with clinical research organizations
  • Advantages of negotiating in USD or investigator’s local currency


Nate Wyne, Senior Foreign Exchange Advisor

Peter Compton, Senior Foreign Exchange Advisor



This article is intended for US audiences only.

About the Author

Peter Compton is a senior foreign exchange advisor for Silicon Valley Bank’s global financial services group, and has been with SVB since 2007. He helps clients design and implement hedging strategies for foreign currency exposures. Compton has over 20 years experience in global financial markets.

Before joining Silicon Valley Bank, Compton spent seven years working in the European equity markets. Based in Germany, he spent four years with HSBC and three years as Head of Equity Sales for ABN-AMRO in Frankfurt. Prior to his work overseas, Compton spent seven years with Bank of America in San Francisco as an equity and fixed income derivative specialist.

Compton holds a bachelor's degree in business and management from the University of Rhode Island and a Master's of Business Administration from San Francisco State University.